News | August 30, 2023
Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Subscribe To Our Newsletter & Stay Updated
